Multivariable analysis of the association between intervention trials research participation and 5-year survival and 30-day postoperative mortality using an optimal cut-point approach
| 5-year survival* | 30-day mortality† | |||||
|---|---|---|---|---|---|---|
| n | HR | 95% CI | n | OR | 95% CI | |
| Participation threshold (≥16% in any individual year) | ||||||
| Low (<16%) | 192 755 | 1.00 | 131 364 | 1.00 | ||
| High (≥16%) | 17 213 | 0.95 | 0.92 to 0.97 | 11 299 | 0.85 | 0.78 to 0.94 |
| Number of years with high participation | ||||||
| 0 years | 150 996 | 1.00 | 102 321 | 1.00 | ||
| 1 year | 25 110 | 0.99 | 0.97 to 1.00 | 17 769 | 0.95 | 0.89 to 1.02 |
| 2 years | 14 679 | 1.01 | 0.98 to 1.03 | 10 360 | 0.93 | 0.85 to 1.02 |
| 3 years | 7407 | 0.90 | 0.87 to 0.93 | 4879 | 0.87 | 0.76 to 0.99 |
| ≥4 years | 11 776 | 0.90 | 0.88 to 0.93 | 7334 | 0.76 | 0.67 to 0.86 |
*Based on 209 968 patients; adjusted for age group, sex, deprivation quintile, Dukes’ stage, tumour site, primary procedure, admission method, screening status, year of diagnosis, annual Trust workload, ECMC status. For the full model results see online supplementary table S3.
†Based on 142 663 patients; adjusted for age group, sex, deprivation quintile, Dukes’ stage, tumour site, admission method, screening status, year of diagnosis, annual Trust workload, ECMC status. For the full model results see online supplementary table S5.
ECMC, Experimental Cancer Medicine Centre.